Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial
- 16 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 32 (9), 1837-1848
- https://doi.org/10.1007/s00198-021-05870-1
Abstract
Summary Some studies indicate potential beneficial effects of metformin on body composition and bone. This trial compared metformin + insulin vs placebo + insulin. Metformin treatment had a small but positive effect on bone quality in the peripheral skeleton, reduced weight gain, and resulted in a more beneficial body composition compared with placebo in insulin-treated patients with type 2 diabetes. Introduction Glucose-lowering medications affect body composition. We assessed the long-term effects of metformin compared with placebo on whole body bone and body composition measures in patients with type 2 diabetes mellitus. Methods This was a sub-study of the Copenhagen Insulin and Metformin Therapy trial, which was a double-blinded randomized placebo-controlled trial assessing 18-month treatment with metformin compared with placebo, in combination with different insulin regimens in patients with type 2 diabetes mellitus (T2DM). The sub-study evaluates the effects on bone mineral content (BMC), density (BMD), and body composition from whole body dual-energy X-ray absorptiometry (DXA) scans which were assessed at baseline and after 18 months. Results Metformin had a small, but positive, (p < 0.05) effect on subtotal, appendicular, and legs BMC and BMD compared with placebo. After adjustment for sex, age, vitamin D, smoking, BMI, T2DM duration, HbA1c, and insulin dose, the effects on appendicular BMC and BMD persisted (p < 0.05 for both). The changes in appendicular BMC and BMD corresponded approximately to a 0.7% and 0.5% increase in the metformin group and 0.4% and 0.4% decrease in the placebo group, respectively. These effects were mostly driven by an increase in BMC and BMD in the legs and a loss of BMC and BMD in the arms. During 18 months, all participants increased in weight, fat mass (FM), FM%, and lean mass (LM), but decreased in LM%. The metformin group increased less in weight (subtotal weight (weight-head) − 2.4 [− 3.5, − 1.4] kg, p value < 0.001) and FM (− 1.5 [− 2.3, − 0.8] kg, p value < 0.001) and decreased less in LM% (0.6 [0.2, 1.1] %, p value < 0.001) compared with the placebo group. Conclusion Metformin treatment had a small positive effect on BMC and BMD in the peripheral skeleton and reduced weight gain compared with placebo in insulin-treated patients with T2DM.Keywords
Funding Information
- Nordsjællands Hospital
- Jascha Fonden
- the Osteoporosis Association for patient
- the foundation of A & J C Tvergaard
- Kaptajnløjtnant Harald Jensens og Hustrus Fond
- Inge and Per Refshalls research grant
- Danish Bone Society travel grant
This publication has 37 references indexed in Scilit:
- Bone Metabolism in Obesity and Weight LossAnnual Review of Nutrition, 2012
- The association between fracture and obesity is site-dependent: A population-based study in postmenopausal womenJournal of Bone and Mineral Research, 2011
- Insulin Sensitizers May Attenuate Lean Mass Loss in Older Men With DiabetesDiabetes Care, 2011
- Relationship of body mass index with main limb fragility fractures in postmenopausal womenJournal of Bone and Mineral Metabolism, 2009
- Study rationale and design of the CIMT trial: The Copenhagen Insulin and Metformin Therapy TrialDiabetes, Obesity and Metabolism, 2009
- Non-weight-bearing effect of trunk and peripheral fat mass on bone mineral density in pre- and post-menopausal womenMaturitas, 2008
- A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapiesCurrent Medical Research and Opinion, 2007
- Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysisOsteoporosis International, 2006
- Body mass index as a predictor of fracture risk: A meta-analysisOsteoporosis International, 2005
- Effects of metformin on the body composition in subjects with risk factors for type 2 diabetesDiabetes, Obesity and Metabolism, 2004